Hatley Oliver J D, Jones Christopher R, Galetin Aleksandra, Rostami-Hodjegan Amin
Certara, Blades Enterprise Centre, Sheffield, S2 4SU, UK.
Centre for Applied Pharmacokinetic Research, University of Manchester, Manchester, M13 9PT, UK.
Biopharm Drug Dispos. 2017 Apr;38(3):187-208. doi: 10.1002/bdd.2070.
The metabolic capacity of the intestine and its importance as the initial barrier to systemic exposure can lead to underestimation of first-pass, and thus overestimation of oral bioavailability. However, the in vitro tools informing estimates of in vivo intestinal metabolism are limited by the complexity of the in vitro matrix preparation and uncertainty with the scaling factors for in vitro to in vivo extrapolation. A number of methods currently exist in the literature for the preparation of intestinal microsomes; however, the impact of key steps in the preparation procedure has not been critically assessed. In the current study, changes in enterocyte isolation, the impact of buffer constituents heparin and glycerol, as well as sonication as a direct method of homogenization were assessed systematically. Furthermore, fresh vs. frozen tissue samples and the impact of microsome freeze thawing was assessed. The rat intestinal microsomes were characterized for CYP content as well as metabolic activity using testosterone and 4-nitropheonol as probes for CYP and UGT activity, respectively. Comparisons in metabolic activity and scaled unbound intestinal intrinsic clearance (CL ) were made to commercially available microsomes using 25 drugs with a diverse range of metabolic pathways and intestinal metabolic stabilities. An optimal, robust and reproducible microsomal preparation method for investigation of intestinal metabolism is proposed. The importance of characterization of the in vitro matrix and the potential impact of intestinal scaling factors on the in vitro-in vivo extrapolation of F needs to be investigated further. © 2017 The Authors Biopharmaceutics & Drug Disposition Published by John Wiley & Sons Ltd.
肠道的代谢能力及其作为全身暴露初始屏障的重要性可能导致首过效应被低估,从而高估口服生物利用度。然而,用于估计体内肠道代谢的体外工具受到体外基质制备复杂性以及体外到体内外推比例因子不确定性的限制。目前文献中有多种制备肠道微粒体的方法;然而,制备过程中关键步骤的影响尚未得到严格评估。在本研究中,系统评估了肠细胞分离的变化、缓冲液成分肝素和甘油的影响以及作为直接匀浆方法的超声处理。此外,还评估了新鲜组织样本与冷冻组织样本以及微粒体冻融的影响。分别使用睾酮和4 - 硝基苯酚作为CYP和UGT活性的探针,对大鼠肠道微粒体的CYP含量以及代谢活性进行了表征。使用25种具有不同代谢途径和肠道代谢稳定性的药物,对代谢活性和按比例计算的未结合肠道内在清除率(CL)与市售微粒体进行了比较。提出了一种用于研究肠道代谢的最佳、稳健且可重复的微粒体制备方法。体外基质表征的重要性以及肠道比例因子对F体外 - 体内外推的潜在影响需要进一步研究。© 2017作者 生物药剂学与药物处置 由John Wiley & Sons Ltd出版